OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection

Nephron. Clinical Practice
Daniel PatschanOliver Witzke

Abstract

The aim of this study was to evaluate long-term allograft salvage rates of patients with steroid refractory allograft rejection after kidney transplantation and to identify factors indicating a successful outcome. Fifty patients with continuing rejection after high-dose steroids were included in the study. Baseline immunosuppression was switched from cyclosporine to tacrolimus in all patients. Twenty patients additionally received OKT3 as antirejection therapy. Patients having received a cadaveric renal transplant in 1995, excluding patients with steroid resistant rejection, were chosen as a control cohort. Patient survival rates were 96% (n = 48) and 90% (n = 45) and allograft survival rates were 66% (n = 33) and 62% (n = 31) after 5 and 7 years following steroid refractory renal allograft rejection. Graft survival within the control cohort was 73% after 5 years and 69% after 7 years. Creatinine clearance increased from 20 +/- 15 ml/min/1.73 m2 at the start of tacrolimus therapy to 37 +/- 29 ml/min/1.73 m2 and to 32 +/- 26 ml/min/1.73 m2 after 5 and 7 years. OKT3 treatment predicted successful rescue therapy (p = 0.005 and p = 0.04 after 5 and 7 years). Our data indicate a reasonable graft survival in steroid refractory renal ...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Feb 1, 1991·Transplantation·T J SchroederM R First
Feb 1, 1987·Transplantation·J R ThistlethwaiteF P Stuart
May 1, 1993·Transplantation·G P BasadonnaJ S Najarian
Jun 19, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D Cantarovich, J P Soulillou
Jun 25, 1998·Transplant International : Official Journal of the European Society for Organ Transplantation·C MariatF Berthoux
Dec 1, 1999·Transplantation Proceedings·F V VeroneseR C Manfro
Dec 9, 2000·Transplant International : Official Journal of the European Society for Organ Transplantation·J WaiserH H Neumayer
May 19, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Yolanda T BeckerHans W Sollinger

❮ Previous
Next ❯

Citations

Oct 23, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.